Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island

Citation
Dj. Simpson et al., Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island, CANCER RES, 60(5), 2000, pp. 1211-1216
Citations number
41
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER RESEARCH
ISSN journal
00085472 → ACNP
Volume
60
Issue
5
Year of publication
2000
Pages
1211 - 1216
Database
ISI
SICI code
0008-5472(20000301)60:5<1211:LOPEIP>2.0.ZU;2-S
Abstract
We recently showed loss of pRb in a proportion of pituitary tumors that was not associated with loss of heterozygosity of an RB1 intragenic marker. To further define the mechanism responsible for loss of retinoblastoma protei n (pRb) expression, we have investigated the methylation status of the CpG island contained within the promoter region of the RB1 gene, together with sequence analysis of the essential promoter region and exons coding for the protein-binding pocket domain. Methylation of the CpG island within the RB 1 promoter region was detected in 6 of 10 tumors that failed to express pRb . In contrast, 18 of 30 tumors and all six histologically normal postmortem pituitaries that expressed pRb were unmethylated, No inactivating mutation s were found within the RB1 promoter region in the four unmethylated tumors that failed to express pRB. However, one or more exons comprising the codi ng region for the protein-binding pocket domain were shown to be homozygous ly deleted in three of four tumors available for analysis. This study descr ibes an additional tumor type, in addition to retinoblastoma, in which meth ylation of the RB1 promoter is associated with loss of pRb expression. Furt hermore, we show that in addition to methylation of the RB1 promoter region , deletion within the protein-binding pocket domain is associated with a lo ss of detectable pRb expression. The reactivation of tumor suppressor genes , silenced through methylation, represents a promising therapeutic target i n sporadic pituitary adenomas.